Thu 21 May 2026 - Public discussion in Singapore raised questions about whether health insurance should cover genetic testing for breast-cancer susceptibility.
This paper synthesises public data to assess the population and cost impact of enhanced screening and BRCA testing, finding that improved mammography participation offers the greatest population-level benefit, while genetic testing is most relevant for targeted high-risk groups.
The analysis highlights trade-offs between clinical benefit, affordability, and risk selection that are relevant to health insurers and policymakers.
Konrad Kuc, FSAS, FASSA
| Members | Book for free |
| Non-members | Book for £45 |